152 research outputs found
Extending Construal Level Theory to Distributed Teams: Perception and Evaluation of Distant Others
Building on prior research on distributed teams that has identified physical and temporal distance as impediments to collaboration and relationship development, this paper explores how and why we treat geographically distant others differently from those who are proximal. According to construal level theory, physically- or temporally-distant events or objects are more psychologically distant and are more likely to be described in terms of their more general characteristics, while views of more proximal events or objects will be more detailed and nuanced. We extend construal level theory to the distributed team context by advancing propositions about how group members perceive and evaluate distant others in contrast to proximal others. By comparing to alternative computer-mediated communication and social psychological theories that have been applied to this phenomenon, we show that construal level theory offers parsimonious explanations as well as novel predictions about how and why we perceive and evaluate distant others differently. The paper then considers theoretical, methodological, and practical implications of construal level theory for distributed teams and other virtual settings
Testing the role of predicted gene knockouts in human anthropometric trait variation
National Heart, Lung, and Blood Institute (NHLBI)
S.L. is funded by a Canadian Institutes of Health Research
Banting doctoral scholarship. G.L. is funded by Genome Canada
and GΓ©nome QuΓ©bec; the Canada Research Chairs program; and
the Montreal Heart Institute Foundation. C.M.L. is supported by
Wellcome Trust (grant numbers 086596/Z/08/Z, 086596/Z/08/A);
and the Li Ka Shing Foundation. N.S. is funded by National Institutes
of Health (grant numbers HL088456, HL111089, HL116747).
The Mount Sinai BioMe Biobank Program is supported by the Andrea
and Charles Bronfman Philanthropies. GO ESP is supported
by NHLBI (RC2 HL-103010 to HeartGO, RC2 HL-102923 to LungGO,
RC2 HL-102924 to WHISP). The ESP exome sequencing was
performed through NHLBI (RC2 HL-102925 to BroadGO, RC2 HL-
102926 to SeattleGO). EGCUT work was supported through the
Estonian Genome Center of University of Tartu by the Targeted
Financing from the Estonian Ministry of Science and Education
(grant number SF0180142s08); the Development Fund of the University
of Tartu (grant number SP1GVARENG); the European Regional
Development Fund to the Centre of Excellence in
Genomics (EXCEGEN) [grant number 3.2.0304.11-0312]; and
through FP7 (grant number 313010). EGCUT were further supported
by the US National Institute of Health (grant number
R01DK075787). A.K.M. was supported by an American Diabetes
Association Mentor-Based Postdoctoral Fellowship (#7-12-MN-
02). The BioVU dataset used in the analyses described were obtained
from Vanderbilt University Medical Centers BioVU which
is supported by institutional funding and by the Vanderbilt CTSA
grant ULTR000445 from NCATS/NIH. Genome-wide genotyping
was funded by NIH grants RC2GM092618 from NIGMS/OD and
U01HG004603 from NHGRI/NIGMS. Funding to pay the Open Access
publication charges for this article was provided by a block
grant from Research Councils UK to the University of Cambridge
Testing the role of predicted gene knockouts in human anthropometric trait variation
National Heart, Lung, and Blood Institute (NHLBI)
S.L. is funded by a Canadian Institutes of Health Research
Banting doctoral scholarship. G.L. is funded by Genome Canada
and GΓ©nome QuΓ©bec; the Canada Research Chairs program; and
the Montreal Heart Institute Foundation. C.M.L. is supported by
Wellcome Trust (grant numbers 086596/Z/08/Z, 086596/Z/08/A);
and the Li Ka Shing Foundation. N.S. is funded by National Institutes
of Health (grant numbers HL088456, HL111089, HL116747).
The Mount Sinai BioMe Biobank Program is supported by the Andrea
and Charles Bronfman Philanthropies. GO ESP is supported
by NHLBI (RC2 HL-103010 to HeartGO, RC2 HL-102923 to LungGO,
RC2 HL-102924 to WHISP). The ESP exome sequencing was
performed through NHLBI (RC2 HL-102925 to BroadGO, RC2 HL-
102926 to SeattleGO). EGCUT work was supported through the
Estonian Genome Center of University of Tartu by the Targeted
Financing from the Estonian Ministry of Science and Education
(grant number SF0180142s08); the Development Fund of the University
of Tartu (grant number SP1GVARENG); the European Regional
Development Fund to the Centre of Excellence in
Genomics (EXCEGEN) [grant number 3.2.0304.11-0312]; and
through FP7 (grant number 313010). EGCUT were further supported
by the US National Institute of Health (grant number
R01DK075787). A.K.M. was supported by an American Diabetes
Association Mentor-Based Postdoctoral Fellowship (#7-12-MN-
02). The BioVU dataset used in the analyses described were obtained
from Vanderbilt University Medical Centers BioVU which
is supported by institutional funding and by the Vanderbilt CTSA
grant ULTR000445 from NCATS/NIH. Genome-wide genotyping
was funded by NIH grants RC2GM092618 from NIGMS/OD and
U01HG004603 from NHGRI/NIGMS. Funding to pay the Open Access
publication charges for this article was provided by a block
grant from Research Councils UK to the University of Cambridge
Testing the role of predicted gene knockouts in human anthropometric trait variation
National Heart, Lung, and Blood Institute (NHLBI)
S.L. is funded by a Canadian Institutes of Health Research
Banting doctoral scholarship. G.L. is funded by Genome Canada
and GΓ©nome QuΓ©bec; the Canada Research Chairs program; and
the Montreal Heart Institute Foundation. C.M.L. is supported by
Wellcome Trust (grant numbers 086596/Z/08/Z, 086596/Z/08/A);
and the Li Ka Shing Foundation. N.S. is funded by National Institutes
of Health (grant numbers HL088456, HL111089, HL116747).
The Mount Sinai BioMe Biobank Program is supported by the Andrea
and Charles Bronfman Philanthropies. GO ESP is supported
by NHLBI (RC2 HL-103010 to HeartGO, RC2 HL-102923 to LungGO,
RC2 HL-102924 to WHISP). The ESP exome sequencing was
performed through NHLBI (RC2 HL-102925 to BroadGO, RC2 HL-
102926 to SeattleGO). EGCUT work was supported through the
Estonian Genome Center of University of Tartu by the Targeted
Financing from the Estonian Ministry of Science and Education
(grant number SF0180142s08); the Development Fund of the University
of Tartu (grant number SP1GVARENG); the European Regional
Development Fund to the Centre of Excellence in
Genomics (EXCEGEN) [grant number 3.2.0304.11-0312]; and
through FP7 (grant number 313010). EGCUT were further supported
by the US National Institute of Health (grant number
R01DK075787). A.K.M. was supported by an American Diabetes
Association Mentor-Based Postdoctoral Fellowship (#7-12-MN-
02). The BioVU dataset used in the analyses described were obtained
from Vanderbilt University Medical Centers BioVU which
is supported by institutional funding and by the Vanderbilt CTSA
grant ULTR000445 from NCATS/NIH. Genome-wide genotyping
was funded by NIH grants RC2GM092618 from NIGMS/OD and
U01HG004603 from NHGRI/NIGMS. Funding to pay the Open Access
publication charges for this article was provided by a block
grant from Research Councils UK to the University of Cambridge
Zelda Binding in the Early Drosophila melanogaster Embryo Marks Regions Subsequently Activated at the Maternal-to-Zygotic Transition
The earliest stages of development in most metazoans are driven by maternally deposited proteins and mRNAs, with widespread transcriptional activation of the zygotic genome occurring hours after fertilization, at a period known as the maternal-to-zygotic transition (MZT). In Drosophila, the MZT is preceded by the transcription of a small number of genes that initiate sex determination, patterning, and other early developmental processes; and the zinc-finger protein Zelda (ZLD) plays a key role in their transcriptional activation. To better understand the mechanisms of ZLD activation and the range of its targets, we used chromatin immunoprecipitation coupled with high-throughput sequencing (ChIP-Seq) to map regions bound by ZLD before (mitotic cycle 8), during (mitotic cycle 13), and after (late mitotic cycle 14) the MZT. Although only a handful of genes are transcribed prior to mitotic cycle 10, we identified thousands of regions bound by ZLD in cycle 8 embryos, most of which remain bound through mitotic cycle 14. As expected, early ZLD-bound regions include the promoters and enhancers of genes transcribed at this early stage. However, we also observed ZLD bound at cycle 8 to the promoters of roughly a thousand genes whose first transcription does not occur until the MZT and to virtually all of the thousands of known and presumed enhancers bound at cycle 14 by transcription factors that regulate patterned gene activation during the MZT. The association between early ZLD binding and MZT activity is so strong that ZLD binding alone can be used to identify active promoters and regulatory sequences with high specificity and selectivity. This strong early association of ZLD with regions not active until the MZT suggests that ZLD is not only required for the earliest wave of transcription but also plays a major role in activating the genome at the MZT
HIV-2 interaction with cell coreceptors: amino acids within the V1/V2 region of viral envelope are determinant for CCR8, CCR5 and CXCR4 usage
Β© 2014 Santos-Costa et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.Background: Human immunodeficiency virus 1 and 2 (HIV-1 and HIV-2) use cellular receptors in distinct ways. Besides a more promiscuous usage of coreceptors by HIV-2 and a more frequent detection of CD4-independent HIV-2 isolates, we have previously identified two HIV-2 isolates (HIV-2MIC97 and HIV-2MJC97) that do not use the two major HIV coreceptors: CCR5 and CXCR4. All these features suggest that in HIV-2 the Env glycoprotein subunits may have a different structural organization enabling distinct - although probably less efficient - interactions with cellular receptors.
Results: By infectivity assays using GHOST cell line expressing CD4 and CCR8 and blocking experiments using CCR8-specific ligand, I-309, we show that efficient replication of HIV-2MIC97 and HIV-2MJC97 requires the presence of CCR8 at plasma cell membrane. Additionally, we disclosed the determinants of chemokine receptor usage at the molecular level, and deciphered the amino acids involved in the usage of CCR8 (R8 phenotype) and in the switch from CCR8 to CCR5 or to CCR5/CXCR4 usage (R5 or R5X4 phenotype). The data obtained from site-directed mutagenesis clearly indicates that the main genetic determinants of coreceptor tropism are located within the V1/V2 region of Env surface glycoprotein of these two viruses.
Conclusions: We conclude that a viral population able to use CCR8 and unable to infect CCR5 or CXCR4-positive cells, may exist in some HIV-2 infected individuals during an undefined time period, in the course of the asymptomatic stage of infection. This suggests that in vivo alternate molecules might contribute to HIV infection of natural target cells, at least under certain circumstances. Furthermore we provide direct and unequivocal evidence that the usage of CCR8 and the switch from R8 to R5 or R5X4 phenotype is determined by amino acids located in the base and tip of V1 and V2 loops of HIV-2 Env surface glycoprotein.This work was supported by grants from: Fundação para a CiΓͺncia e Tecnologia (FCT; PPCDT/SAU-IMI/55726/2004); Fundação para a CiΓͺncia e Tecnologia and MinistΓ©rio da SaΓΊde de Portugal (VIH/SAU/0006/2011); and from Gilead Sciences Portugal (Programa Gilead GΓ©nese).info:eu-repo/semantics/publishedVersio
Molecular mechanisms of EGF signaling-dependent regulation of pipe, a gene crucial for dorsoventral axis formation in Drosophila
During Drosophila oogenesis the expression of the sulfotransferase Pipe in ventral follicle cells is crucial for dorsoventral axis formation. Pipe modifies proteins that are incorporated in the ventral eggshell and activate Toll signaling which in turn initiates embryonic dorsoventral patterning. Ventral pipe expression is the result of an oocyte-derived EGF signal which down-regulates pipe in dorsal follicle cells. The analysis of mutant follicle cell clones reveals that none of the transcription factors known to act downstream of EGF signaling in Drosophila is required or sufficient for pipe regulation. However, the pipe cis-regulatory region harbors a 31-bp element which is essential for pipe repression, and ovarian extracts contain a protein that binds this element. Thus, EGF signaling does not act by down-regulating an activator of pipe as previously suggested but rather by activating a repressor. Surprisingly, this repressor acts independent of the common co-repressors Groucho or CtBP
Autoimmune disease in mothers with the FMR1 premutation is associated with seizures in their children with fragile X syndrome
An increased prevalence of autoimmune diseases in family members of children with autism spectrum disorders (ASD) has been previously reported. ASD is also a common problem co-occurring in children with fragile X syndrome (FXS). Why ASD occurs in some individuals with FXS, but not all, is largely unknown. Furthermore, in premutation carrier mothers, there is an increased risk for autoimmune diseases. This study compared the rate of ASD and other neurodevelopmental/behavioral problems in 61 children with FXS born to 41 carrier mothers who had autoimmune disease and in 97 children with FXS of 78 carrier mothers who did not have autoimmune disease. There were no significant differences in the mean age (9.61Β Β±Β 5.59 vs. 9.41Β Β±Β 6.31, PΒ =Β 0.836), cognitive and adaptive functioning in children of mothers with and without autoimmune disease. Among children whose mothers had autoimmune disease, the odds ratio (OR) for ASD was 1.27 (95% CI 0.62β2.61, PΒ =Β 0.5115). Interestingly, the OR for seizures and tics was 3.81 (95% CI 1.13β12.86, PΒ =Β 0.031) and 2.94 (95% CI 1.19β7.24, PΒ =Β 0.019), respectively, in children of mothers with autoimmune disease compared to children of mothers without autoimmune disease. In conclusion, autoimmune disease in carrier mothers was not associated with the presence of ASD in their children. However, seizures and tics were significantly increased in children of mothers with autoimmune disease. This suggests a potential new mechanism of seizure and tic exacerbation in FXS related to an intergenerational influence from autoimmunity in the carrier mother
Macrophages in Breast Cancer: Do Involution Macrophages Account for the Poor Prognosis of Pregnancy-Associated Breast Cancer?
Macrophage influx is associated with negative outcomes for women with breast cancer and has been demonstrated to be required for metastasis of mammary tumors in mouse models. Pregnancy-associated breast cancer is characterized by particularly poor outcomes, however the reasons remain obscure. Recently, post-pregnancy mammary involution has been characterized as having a wound healing signature. We have proposed the involution-hypothesis, which states that the wound healing microenvironment of the involuting gland is tumor promotional. Macrophage influx is one of the prominent features of the involuting gland, identifying the macrophage a potential instigator of tumor progression and a novel target for breast cancer treatment and prevention
- β¦